Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

被引：0
|
作者：
Inzucchi, Silvio E. [1 ]
Wanner, Christoph [2 ]
Lachin, John M. [3 ]
Fitchett, David [4 ]
Bluhmki, Erich [5 ]
Hantel, Stefan [5 ]
Mattheus, Michaela [6 ]
Devins, Theresa [7 ]
Johansen, Odd Erik [8 ]
Woerle, Hans Juergen [8 ]
Broedl, Uli C. [9 ]
Zinman, Bernard [10 ,11 ,12 ]
机构：
[1] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
[2] Wurzburg Univ Clin, Div Nephrol, Dept Med, Wurzburg, Germany
[3] George Washington Univ, Biostat Unit, Rockville, MD USA
[4] St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Biberach, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Ingelheim, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Clin Operat, Ridgefield, CT USA
[8] Boehringer Ingelheim Norway KS, Therapeut Area Metab, Asker, Norway
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[10] Mt Sinai Hosp, Lunenfeld Tanenbaum Rsch Inst, Toronto, ON M5G 1X5, Canada
[11] Mt Sinai Hosp, Div Endocrinol, Toronto, ON M5G 1X5, Canada
[12] Univ Toronto, Toronto, ON, Canada
来源：
CIRCULATION | 2015年 / 132卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
20238
引用
收藏
页码：2271 / 2271
页数：1
相关论文
共 50 条
  • [21] Reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Nicholls, Stephen J.
    Ryden, Lars
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 : S1 - S1
  • [22] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsapas, Apostolos
    Kourlaba, Georgia
    Papageorgiou, Giannis
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 417 - 426
  • [23] COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
    Gourzoulidis, G.
    Tzanetakos, C.
    Ioannidis, I.
    Tsapas, A.
    Kourlaba, G.
    Papageorgiou, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [24] BUDGET IMPACT ANALYSIS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
    Gourzoulidis, G.
    Tzanetakos, C.
    Ioannidis, T.
    Tsapas, A.
    Kourlaba, G.
    Papageorgiou, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A476 - A476
  • [25] Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Apostolos Tsapas
    Georgia Kourlaba
    Giannis Papageorgiou
    Nikos Maniadakis
    Clinical Drug Investigation, 2018, 38 : 417 - 426
  • [26] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [27] Cardiovascular risk in type 2 diabetes mellitus
    Hohberg, C.
    Roth, W.
    Luebben, G.
    Forst, T.
    Gauert, S.
    Karagiannis, F.
    Reimer, T.
    Gottschall, V.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2007, 16 (03): : 173 - 177
  • [28] Cardiovascular risk factors in patients of type 2 diabetes mellitus with and without cardiovascular complications
    Aasvee, KE
    Kurvinen, E
    Roovere, T
    Tupits, H
    Hedman, A
    Jauhiainen, M
    Sundvall, J
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 152 - 152
  • [29] Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time
    van de Borne, P.
    Selvanayagam, J.
    George, J.
    Lee, J.
    Mattheus, M.
    Woerle, H. -J.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S535
  • [30] BUDGET IMPACT ANALYSIS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HIGH RISK OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN GREECE
    Tzanetakos, C.
    Gourzoulidis, G.
    Papanas, N.
    Papageorgiou, G.
    Karpouzos, G.
    Saloustros, I
    Kourlaba, G.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
12345